chloroquin
cq
hydroxyl
analogu
hydroxychloroquin
hcq
weak
base
halfcenturi
long
use
antimalari
agent
apart
antimalari
activ
cq
hcq
gain
interest
field
infecti
diseas
one
interest
mechan
action
cq
lead
alkalinis
acid
vesicl
inhibit
growth
sever
intracellular
bacteria
fungi
proof
concept
effect
first
use
restor
intracellular
ph
allow
antibiot
efficaci
coxiella
burnetii
agent
q
fever
doxycyclin
plu
hcq
refer
treatment
chronic
q
fever
also
strong
evid
similar
effect
vitro
tropheryma
whipplei
agent
whippl
diseas
clinic
trial
progress
bacteria
fungi
multipli
acid
environ
encourag
vitro
data
suggest
concept
may
generalis
intracellular
organ
multipli
acid
environ
virus
cq
led
inhibit
uncoat
andor
alter
posttransl
modif
newli
synthesis
protein
especi
inhibit
glycosyl
effect
well
describ
vitro
mani
virus
human
immunodefici
viru
hiv
studi
preliminari
vivo
clinic
trial
suggest
cq
alon
combin
antiretrovir
drug
might
repres
interest
way
treat
hiv
infect
conclus
review
reemphasis
paradigm
activ
mediat
lysosomotrop
agent
may
offer
interest
weapon
face
present
futur
infecti
diseas
worldwid
cq
known
sinc
emerg
first
part
centuri
effect
quinin
substitut
drug
choic
malaria
prove
among
success
antimalari
drug
worldwid
scale
owe
wide
deploy
coincid
geograph
distribut
plasmodium
high
intrins
antiparasit
efficaci
low
toxic
concomit
gradual
decreas
use
therapi
prophylaxi
plasmodiuminduc
diseas
worldwid
relat
emerg
cqresist
parasit
cq
hydroxyl
analogu
hcq
gain
interest
field
infecti
diseas
mechan
action
cq
multipl
differ
accord
pathogen
well
elucid
microorgan
cq
hcq
enter
cell
nonproton
form
becom
proton
accord
hendersonhasselbach
law
ie
manner
invers
proport
ph
therefor
concentr
within
acid
organel
includ
endosom
lysosom
golgi
vesicl
increas
ph
last
decad
two
main
mechan
action
cq
well
describ
ie
alkalinis
acid
vesicl
cell
infect
intracellular
bacteria
fungi
alter
posttransl
modif
newli
synthesis
protein
cell
infect
virus
proof
concept
use
cq
antiinfecti
agent
antimalari
agent
fulli
demonstr
first
time
vitro
vivo
model
chronic
q
fever
concept
initi
base
cellular
biolog
find
mainli
manipul
ph
acid
vacuol
coxiella
burnetii
agent
q
fever
live
multipli
demonstr
neg
effect
growth
c
burnetii
lysosomotrop
agent
first
step
follow
demonstr
alkalinis
c
burnetiicontain
vacuol
could
restor
intracellular
activ
antibiot
fig
paradigm
later
use
demonstr
clinic
efficaci
associ
doxycyclin
hcq
treatment
chronic
q
fever
endocard
regimen
refer
treatment
date
model
confirm
clinic
efficaci
fig
strong
evid
effect
intracellular
bacteria
especi
tropheryma
whipplei
agent
whippl
diseas
multipli
phagosom
sinc
agent
increas
intravacuolar
ph
decreas
bacteri
viabil
analog
c
burnetii
hcq
restor
intracellular
activ
doxycyclin
vitro
clinic
trial
use
regimen
evalu
sever
bacteria
fungi
live
multipli
acid
vacuol
preliminari
vitro
data
encourag
use
cq
infect
virus
cq
led
inhibit
lowphdepend
entri
step
alter
posttransl
modif
newli
synthesis
protein
especi
via
inhibit
glycosyl
effect
well
describ
vitro
mani
virus
human
immunodefici
viru
studi
moreov
preliminari
vivo
clinic
trial
suggest
cq
alon
combin
antiretrovir
drug
might
repres
interest
way
treat
hiv
infect
review
avail
vitro
vivo
data
effect
cqhcq
bacteri
fungal
viral
infect
concept
manipul
intracellular
ph
cell
modif
glycosyl
protein
lysosomotrop
agent
instead
antimicrobi
compound
power
approach
new
therapeut
strategi
prevent
therapeut
manag
sever
infecti
diseas
includ
great
public
health
concern
worldwid
cqhcq
also
antiinflammatori
properti
howev
discuss
review
intracellular
locat
sever
bacteria
fungi
known
decad
critic
point
explain
failur
antibiot
treatment
erad
pathogen
host
cell
intracellular
pathogen
evad
firstlin
antimicrobi
defenc
includ
attack
phagocyt
fig
internalis
cell
usual
format
phagosom
rapidli
fuse
lysosom
bacteria
kill
oxygendepend
oxygenindepend
kill
mechan
lead
acidif
phagolysosom
ph
acid
activ
lysosom
enzym
intracellular
pathogen
may
evad
lysosom
pathway
sever
mechan
lifestyl
lysosom
freecel
erythrocyt
bartonella
spp
ii
escap
phagosom
fusion
lysosom
multipl
cytosol
rickettsia
shigella
fig
iii
inhibit
phagolysosom
fusion
multipl
phagosom
chlamydia
ehrlichia
legionella
salmonella
yersinia
brucella
mycobacterium
francisella
histoplasma
capsulatum
aspergillu
fumigatu
fig
iv
surviv
multipl
phagolysosom
c
burnetii
whipplei
staphylococcu
aureu
candida
albican
cryptococcu
neoforman
fig
mani
argument
suggest
low
ph
environ
within
phagosom
compart
cell
critic
mani
intracellular
pathogen
access
cellular
iron
growth
cq
treatment
differ
cell
includ
macrophag
could
inhibit
growth
sever
intracellular
bacteria
neutralis
phagolysosom
ph
tabl
fig
thu
two
main
mechan
explain
intracellular
bacteri
inhibit
cq
phdepend
iron
depriv
direct
toxic
increas
phagolysosom
ph
harm
growth
sever
intracellular
pathogen
c
burnetii
whipplei
coxiella
burnetii
agent
q
fever
strict
intracellular
bacterium
abl
surviv
phagolysosom
low
ph
ph
necessari
metabol
q
fever
includ
acut
manifest
mainli
pneumon
hepat
chronic
form
mainli
endocard
usual
regimen
doxycyclin
mg
per
day
week
recommend
patient
acut
q
fever
present
treatment
acut
q
fever
suffici
prevent
develop
chronic
q
fever
thu
reliabl
antibiot
therapi
chronic
infect
challeng
problem
sinc
antibiot
bactericid
vitro
c
burnetii
ph
c
burnetiicontain
phagolysosom
rais
use
basic
lysosomotrop
agent
cq
methylamin
ammonium
chlorid
bacteri
multipl
inhibit
show
direct
neg
effect
growth
lysosomotrop
agent
includ
cq
origin
kill
assay
model
develop
maurin
et
al
demonstr
doxycyclin
pefloxacin
rifampicin
show
signific
bactericid
activ
convers
shown
vitro
intracellular
antibiot
activ
restor
correl
modif
ph
lysosomotrop
agent
fig
lack
bactericid
activ
probabl
due
inactiv
low
ph
phagolysosom
c
burnetii
surviv
addit
lysosomotrop
alkalinis
agent
ie
cq
antibiot
improv
activ
doxycyclin
pefloxacin
becam
bactericid
model
bacteria
activ
multipli
acid
ph
good
paradigm
demonstr
lack
bactericid
effect
antibiot
due
intraphagolysosom
acid
vitro
find
evalu
mani
vivo
studi
treatment
patient
chronic
q
fever
endocard
use
combin
doxycyclin
hcq
gml
serum
month
inde
prior
treatment
patient
treat
longterm
tabl
bacteria
fungi
virus
inhibit
chloroquin
andor
hydroxychloroquin
vitro
data
refer
fungi
refer
viru
refer
coxiella
burnetii
histoplasma
capsulatum
hiv
tropheryma
whipplei
cryptococcu
neoforman
sarscov
legionella
pneumophila
paracoccidioid
brasiliensi
influenza
virus
francisella
tularensi
penicillium
marneffei
flaviviru
includ
yellow
fever
viru
mycobacterium
tuberculosi
aspergillu
fumigatu
rubella
viru
tetracyclin
quinolon
regimen
least
year
high
percentag
relaps
regimen
compar
combin
doxycyclin
hydroxychloroquin
sulphat
patient
suffer
q
fever
endocard
patient
treat
doxycyclin
quinolon
com
binat
die
relaps
retreat
switch
new
regimen
still
treat
consid
cure
use
regimen
mean
durat
therapi
cure
group
month
median
month
twentyon
patient
receiv
doxycyclin
hcq
regimen
patient
die
surgic
complic
still
treat
cure
current
evalu
two
patient
treat
month
none
patient
treat
month
relaps
mean
durat
treatment
group
month
median
month
regimen
allow
reduct
durat
therapi
month
mani
patient
also
reduc
relaps
rate
regimen
current
therapi
treatment
chronic
q
fever
cq
use
therapeut
dosag
may
deleteri
effect
includ
risk
retinopathi
necessit
regular
ophthalmolog
examin
cq
level
serum
monitor
ensur
maintain
mgl
similarli
hivinfect
patient
q
fever
endocard
success
treat
valvular
replac
combin
doxycyclin
hcq
combin
treatment
probabl
also
indic
case
c
burnetii
vascular
graft
infect
report
recent
similarli
retrospect
studi
patient
diagnos
q
fever
evalu
risk
develop
endocard
accord
regimen
antibiot
given
patient
regimen
compar
patient
receiv
treatment
develop
chronic
infect
develop
chronic
infect
receiv
doxycyclin
alon
week
month
none
receiv
doxycyclin
hcq
month
develop
chronic
infect
regimen
contain
hcq
found
significantli
superior
prevent
q
fever
endocard
compar
doxycyclin
alon
p
signific
differ
found
treatment
doxycyclin
alon
treatment
establish
develop
q
fever
endocard
may
prevent
search
minor
valvulopathi
echocardiographi
follow
diagnosi
acut
q
fever
treatment
combin
doxycyclin
hcq
year
final
four
case
q
fever
osteoarticular
infect
two
tenosynov
two
spondylodisc
complic
paravertebr
abscess
eventu
cure
use
combin
doxycyclin
hcq
whippl
diseas
invari
fatal
advent
antibiot
howev
current
therapeut
recommend
base
therapeut
trial
adjust
accord
suscept
whipplei
variou
antimicrobi
agent
sinc
bacteria
isol
follow
isol
bacteria
shown
vacuol
acidif
critic
surviv
whipplei
phagosom
sinc
agent
increas
intravacuolar
ph
decreas
bacteri
viabil
fig
analog
c
burnetii
demonstr
doxycyclin
alon
bactericid
whipplei
vitro
cell
model
alkalinis
hcq
may
restor
activ
regimen
base
observ
doxycyclin
hcq
thu
far
success
bactericid
regimen
whipplei
vitro
whether
regimen
work
gener
clinic
set
remain
establish
success
four
patient
two
classic
whippl
diseas
two
blood
cultureneg
endocard
staphylococcu
aureu
facult
intracellular
bacterium
resid
within
phagolysosom
intracellular
locat
certain
strain
aureu
serv
reservoir
bacteria
thought
import
therapi
recurr
infect
human
chronic
staphylococc
mastiti
dairi
cow
although
aminoglycosid
bactericid
extracellular
staphylococci
ineffect
reduc
intracellular
form
microorgan
hypothesis
diminish
suscept
intracellular
aureu
may
relat
acid
ph
within
phagolysosom
demonstr
alkalinis
aureuscontain
vacuol
could
restor
intracellular
activ
aminoglycosid
furthermor
intracellular
kill
aureu
correl
well
increas
lysosom
ph
due
lysosomotrop
alkalinis
agent
recent
demonstr
cq
ammonium
chlorid
significantli
enhanc
intracellular
kill
levofloxacin
bactericid
activ
levofloxacin
partial
restor
ph
neutralis
bactericid
activ
moxifloxacin
abolish
intracellular
salt
medium
partial
restor
ph
rais
similarli
alkalinis
phagolysosom
significantli
enhanc
intracellular
kill
moxifloxacin
model
bovin
mastiti
due
aureu
clearli
demonstr
low
intraphagolysosom
ph
affect
abil
antibiot
kill
intracellular
bacteria
sinc
activ
rifampicin
enhanc
ph
similar
reason
probabl
explain
rifampicin
penetr
within
eukaryot
cell
activ
acid
ph
display
bactericid
activ
intracellular
aureu
legionella
pneumophila
strict
intracellular
bacterium
multipli
human
mononuclear
phagocyt
respons
legionnair
diseas
cellular
iron
metabol
critic
import
l
pneumophila
sinc
multipl
depend
upon
avail
intracellular
iron
demonstr
cq
ammonium
chlorid
inhibit
intracellular
multipl
l
pneumophila
limit
avail
iron
bacterium
thu
cq
may
interfer
intracellular
iron
metabol
recycl
iron
ferritin
block
degrad
ferritin
acid
proteas
francisella
tularensi
bv
tularensi
f
tularensi
bv
palearctica
facult
intracellular
bacteria
respons
tularaemia
demonstr
f
tularensi
find
success
nich
replic
acidifi
vacuol
iron
concentr
growth
f
tularensi
murin
macrophag
shown
dramat
inhibit
vitro
cq
dosedepend
manner
intracellular
localis
acid
vesicl
facilit
avail
iron
essenti
francisella
growth
surviv
tactic
bacterium
iron
deplet
one
mechan
macrophag
use
inhibit
growth
cq
report
inhibit
intracellular
multipl
mycobacterium
tuberculosi
human
monocytederiv
macrophag
mous
periton
macrophag
seem
possibl
cq
inhibit
tuberculosi
intracellular
multipl
rais
intracellular
ph
limit
avail
iron
bacterium
l
pneumophila
similarli
demonstr
addit
cq
result
signific
reduct
intracellular
growth
mycobacterium
avium
bone
marrowderiv
macrophag
vitro
activ
cq
andor
hcq
demonstr
bacteria
includ
salmonella
enterica
serovar
typhi
escherichia
coli
bacillu
anthraci
bacillu
subtili
borrelia
burgdorferi
brucella
abortu
listeria
monocytogen
tabl
fig
bacteria
may
good
candid
clinic
use
cqhcq
recent
vitro
studi
indic
cq
may
also
interest
activ
fungal
diseas
fig
tabl
includ
mainli
h
capsulatum
c
neoforman
intracellular
h
capsulatum
adapt
surviv
within
mammalian
phagolysosom
resid
within
membranebound
phagosom
fulli
acidifi
histoplasma
capsulatum
abl
maintain
phagosom
ph
inhibit
phagolysosom
fusion
express
uniqu
endogen
h
atpas
buffer
phagosom
ph
demonstr
cq
induc
antihistoplasm
state
macrophag
restrict
phdepend
releas
iron
within
phagolysosom
similarli
cq
shown
kill
c
neoforman
mechan
independ
iron
depriv
inde
unlik
h
capsulatum
c
neoforman
abl
maintain
phagolysosom
milieu
ca
ph
addit
cq
increas
phagolysosom
ph
allow
inhibit
growth
alkalin
ph
report
fumigatu
abil
inhibit
fusion
phagosom
lysosom
cq
may
increas
kill
fungu
macrophag
phdepend
mechan
cq
shown
inhibit
intramacrophag
growth
penicillium
marneffei
opportunist
fungu
caus
dissemin
infect
acquir
immun
defici
syndrom
aid
patient
increas
intravacuolar
ph
disrupt
phdepend
metabol
process
decreas
intracellular
iron
concentr
result
impair
function
sever
cellular
enzym
subsequ
deleteri
effect
critic
step
replic
cellular
dna
gene
express
final
effect
cq
multipl
paracoccidioid
brasiliensi
studi
human
monocyt
murin
paracoccidioidomycosi
model
cq
demonstr
abl
kill
p
brasiliensi
grown
human
monocyt
effect
cq
revers
fenta
iron
compound
solubl
neutral
alkalin
ph
holotransferrin
releas
iron
acid
environ
thu
cq
inhibit
p
brasiliensi
surviv
human
monocyt
iron
depriv
tabl
mechan
antivir
activ
fig
ph
increas
induc
cqhcq
within
acid
organel
includ
endosom
lysosom
golgi
vesicl
involv
antivir
activ
via
two
main
mechan
first
drug
might
respons
inhibit
virus
requir
phdepend
step
entri
host
cell
inde
mani
virus
lowphdepend
conform
chang
trigger
fusion
penetr
andor
uncoat
virus
endocytosi
crucial
due
acidif
occur
within
endosom
pathway
thu
mechan
antivir
effect
depend
extent
viru
use
endosom
entri
instanc
shibata
et
al
found
cq
might
prevent
uncoat
influenza
b
viru
increas
lysosom
ph
critic
valu
requir
induc
fusion
viru
envelop
lysosom
membran
cq
also
found
inhibit
uncoat
hepat
viru
hav
second
cqhcq
might
inhibit
posttransl
modif
viru
envelop
glycoprotein
proteas
glycosyltransferas
within
transgolgi
network
endoplasm
vesicl
inde
enzym
requir
low
ph
activ
cqhcq
might
therefor
lead
decreas
viral
infect
impair
envelop
matur
flavivirida
exampl
virus
cq
could
act
antivir
inhibit
envelop
matur
pathway
alter
proteolyt
process
prm
protein
also
put
mechan
activ
alter
glycosyl
pattern
amino
acid
charg
within
sever
region
viral
envelop
protein
instanc
reduct
number
potenti
nlink
glycosyl
site
within
region
might
provid
alter
immun
escap
broaden
antibodi
repertoir
observ
savarino
et
al
previous
found
cq
decreas
infect
newli
produc
well
abil
cell
form
syncitia
associ
structur
chang
recent
data
suggest
cq
may
respons
inhibit
biosynthesi
sialic
acid
inde
recent
observ
drug
inhibit
cellular
enzym
involv
sialic
acid
biosynthesi
might
repres
major
antivir
mechan
sinc
sialic
acid
compon
envelop
glycoprotein
cqhcq
may
also
indirect
antivir
effect
inde
cq
found
effect
prevent
spread
sever
acut
respiratori
syndrom
sar
associ
coronaviru
cov
cell
cultur
interf
termin
glycosyl
cellular
receptor
angiotensinconvert
enzym
sialic
acid
biosynthesi
might
inhibit
cqhcq
compon
receptor
sarscov
orthomyxovirus
addit
two
main
mechan
possibl
mechan
immunomodulatori
antiinflammatori
properti
suggest
howev
discuss
present
review
vitro
activ
hcqcq
report
wide
rang
virus
frequent
experi
aim
studi
cycl
replic
pathway
use
cq
especi
mechan
virus
penetr
host
cell
tabl
fig
inhibitori
concentr
cq
fell
within
moll
rang
depend
antivir
cq
dose
virus
target
assay
use
assess
antivir
effect
importantli
concentr
rang
clinic
achiev
plasma
malaria
therapi
vari
moll
moll
studi
vitro
effect
cqhcq
hiv
moreov
vivo
studi
quasiexclus
concern
probabl
due
high
morbid
mortal
relat
worldwid
need
lowcost
antiretrovir
therapi
resourcepoor
countri
cqhcq
larg
shown
inhibit
hiv
replic
vitro
importantli
inhibit
observ
sever
cell
line
model
also
lymphocyt
monocyt
peripher
blood
antihiv
effect
demonstr
either
presenc
high
concentr
cqhcq
prior
infect
cell
incub
hivinfect
cell
cq
concentr
similar
found
peripher
blood
individu
chronic
treat
cq
thu
data
suggest
prevent
cur
effect
drug
hiv
concentr
inhibit
viral
replic
ic
rang
moll
moll
variou
hiv
strain
cultur
cell
studi
savarino
et
al
boelaert
et
al
describ
addit
inhibit
replic
hydroxyurea
plu
didanosin
ddi
zidovudin
cq
ic
moll
cell
line
moll
primari
cell
cqinduc
toxic
apoptosi
note
interestingli
accord
vitro
data
cqhcq
also
appear
activ
mostli
circul
west
africa
well
differ
subtyp
deserv
attent
sinc
strain
establish
suggest
natur
resist
sever
antiretrovir
drug
nonnucleosid
revers
transcriptas
inhibitor
like
proteas
inhibitor
pi
activ
cqhcq
observ
vivo
studi
sinc
two
small
phase
ii
randomis
doubleblind
studi
includ
patient
cell
count
cellsmm
compar
reduct
plasma
rna
level
individu
treat
hcq
versu
either
placebo
zidovudin
trial
twothird
patient
antiretroviralna
first
trial
week
treatment
mg
hcq
per
day
result
signific
mean
log
reduct
load
p
wherea
signific
decreas
observ
placebo
arm
patient
arm
concomitantli
percentag
lymphocyt
remain
stabl
hcq
group
wherea
significantli
decreas
placebo
arm
p
second
trial
patient
receiv
hcq
zidovudin
respect
week
load
significantli
reduc
group
log
copiesml
log
copiesml
respect
interestingli
patient
hcq
group
versu
patient
zidovudin
group
show
increas
rna
level
two
recent
noncontrol
studi
report
singapor
patient
load
copiesml
cell
count
cellsmm
receiv
hcq
mg
hydroxyurea
ddi
twice
daili
week
result
log
decreas
plasma
rna
level
rna
level
reduc
compar
baselin
mean
decreas
log
copiesml
patient
complet
cours
therapi
drug
resist
mutat
detect
patient
time
point
anoth
studi
india
patient
count
receiv
lamivudin
hydroxyurea
cq
mg
twice
daili
month
load
reduct
signific
log
reach
undetect
level
patient
median
rise
count
cellsmm
altogeth
vivo
data
patient
nonsever
immunosuppress
cell
count
least
suggest
resist
cqhcq
alon
combin
antiretrovir
drug
might
develop
easili
contrast
addit
cq
zidovudin
ddi
regimen
provid
signific
improv
viroimmunolog
paramet
children
recent
studi
thailand
interest
note
accumul
cq
colostrum
cell
african
mother
take
mg
cq
per
day
observ
suggest
drug
could
potenti
activ
adjuv
postnat
antiretrovir
prophylaxi
mothertochild
transmiss
decreas
load
milk
geograph
area
vertic
transmiss
great
concern
sever
set
cqhcq
use
combin
antivir
drug
question
whether
associ
may
addit
synergist
addit
effect
cq
zidovudin
shown
might
also
exist
associ
ddi
hydroxyurea
furthermor
combin
effect
cq
pi
synergist
doseindepend
manner
savarino
et
al
show
cq
combin
pi
carri
combin
inhibitori
effect
pglycoprotein
multidrug
resist
protein
involv
efflux
pi
major
class
antiretrovir
interestingli
synerg
cq
pi
associ
decreas
threshold
suscept
pi
resist
isol
note
cq
major
substrat
cytochrom
nevirapin
nonnucleosid
revers
transcriptas
inhibitor
hiv
pi
well
recognis
induc
inhibitor
respect
thu
latter
drug
might
subsequ
decreas
increas
levelseffect
cq
shown
endosom
transport
need
human
coronaviru
cell
treat
cq
display
reduc
express
viral
antigen
recent
cq
found
strong
antivir
effect
sarscov
infect
cell
cultur
treat
either
exposur
viru
even
h
follow
infect
suggest
prophylact
therapeut
effect
keyaert
et
al
studi
cq
inhibit
viral
replic
effect
concentr
ec
moll
note
dose
induc
cytostat
activ
much
higher
moll
potenti
mechan
action
cq
coronavirus
underglycosyl
identifi
function
cellular
receptor
sarscov
spike
protein
alter
cq
sarscov
spike
protein
controversi
phrelat
reduct
transduct
sarscov
pseudotyp
virus
also
suggest
note
biot
et
al
recent
report
design
synthesi
hydroxyferroquin
deriv
antimalari
antihiv
antisarscov
activ
activ
cq
orthomyxovirida
influenza
b
virus
describ
sever
decad
vitro
assay
avian
influenza
viru
strain
ongo
shibata
et
al
result
suggest
cq
prevent
uncoat
influenza
b
viru
ooi
et
al
found
ic
valu
cq
influenza
virus
moll
moll
respect
recent
studi
blanchard
et
al
found
pretreat
target
cell
cq
inhibit
hepat
c
viru
hcv
clone
propag
cell
cultur
suggest
hcv
like
flavivirus
pestivirus
enter
cell
clathrinmedi
endocytosi
fusion
within
acid
endosom
compart
cq
also
found
activ
hepat
b
viru
hbv
duck
hbv
contrast
anoth
studi
infect
human
hepatocyt
cultur
hbv
found
unaffect
cq
seven
patient
histolog
proven
chronic
activ
hepat
b
treat
mg
cq
median
month
patient
alanin
aminotransferas
alt
return
normal
valu
prothrombin
time
improv
interestingli
alt
increas
three
patient
follow
inadvert
cq
withdraw
return
prior
level
readministr
four
patient
repeat
liver
biopsi
year
later
reveal
inact
cirrhosi
recent
enhanc
cq
human
tcell
cell
respons
hbv
antigen
observ
inhibit
cq
hepat
viru
hav
uncoat
replic
also
describ
major
advantag
cqhcq
limit
prevent
toxic
long
experi
use
drug
treatment
malaria
alreadi
demonstr
safeti
shortterm
administr
human
moreov
cqhcq
wide
use
chronic
administr
rheumat
diseas
chronic
q
fever
antimalari
prophylaxi
sever
year
low
incid
advers
effect
even
pregnanc
main
advers
effect
report
longterm
administr
drug
macular
retinopathi
due
cumul
dose
could
prevent
regular
visual
monitor
cours
treatment
summari
cqhcq
sever
advantag
antimicrobi
agent
includ
multipl
potenti
mechan
broad
spectrum
activ
clinic
achiev
plasma
concentr
togeth
well
known
limit
toxic
low
cost
two
major
concept
emerg
explain
activ
cqhcq
name
alkalinis
phagolysosom
intracellular
bacteria
fungi
inhibit
entri
step
protein
glycosyl
virus
pioneer
model
infecti
diseas
could
treat
manipul
intracellular
ph
lysosomotrop
agent
chronic
q
fever
review
reemphasis
c
burnetii
paradigm
activ
mediat
lysosomotrop
agent
could
generalis
intracellular
pathogen
live
acid
vacuol
requir
low
ph
multipl
may
offer
interest
weapon
face
present
futur
infecti
diseas
worldwid
fund
none
compet
interest
none
declar
ethic
approv
requir
